Multiple independent, authoritative sources consistently confirm every element of the claim. The trial was two years in duration, placebo-controlled, and double-blinded. It enrolled exactly 365 adults aged 55–80. The study is registered on ClinicalTrials.gov (NCT03613844) and published in eBioMedicine (DOI: 10.1016/j.ebiom.2026.106316), providing a traceable primary record.

• ScienceDaily (the original source URL in the claim) states the study included '365 adults between the ages of 55 and 80' and describes it as a 'two-year, placebo-controlled, double-blinded clinical trial.'
• Keck Medicine of USC's own press release (news.keckmedicine.org) independently confirms '365 adults, ages 55 to 80' in a 'two-year, placebo-controlled, double-blinded study.'
• MedicalXpress also confirms '365 adults, ages 55 to 80' in a 'two-year, placebo-controlled, double-blind study.'
• A forum post (s4me.info) citing the published eBioMedicine paper's methods section directly states it was 'a phase IIa 24-month, randomised, double-blind, placebo-controlled trial (NCT03613844)' with participants 'aged 55–80 years.'
• StudyFinds cross-references the ClinicalTrials.gov registration number NCT03613844 and eBioMedicine article 106316, confirming the trial design details are officially registered and published.

While all secondary sources are consistent, full verification of the exact enrollment figure (365) against the registered trial protocol on ClinicalTrials.gov (NCT03613844) or the full eBioMedicine paper was not directly possible, as those pages were not retrieved in the search results; however, the convergence of multiple independent outlets and the institution's own press release provides strong corroborating evidence.

The specific claim is directly and consistently confirmed across multiple independent, reputable sources reporting on the same peer-reviewed clinical trial published in eBioMedicine (2026). The trial, a randomised, double-blind, placebo-controlled study of 365 older adults at elevated Alzheimer's risk, measured DHA levels in cerebrospinal fluid and found an average 17% increase after six months of 2,000 mg/day DHA supplementation, confirming CNS target engagement. The claim accurately reflects the published finding, including the 17% figure, the six-month measurement point, and the use of CSF as the biomarker for brain delivery.

• ScienceDaily (the original article's source) reports: 'After six months, DHA levels had increased by an average of 17%, confirming that the nutrient had successfully reached its intended destination.' (sciencedaily.com, June 2026)
• Keck Medicine of USC's official press release confirms: 'an average 17% increase of DHA levels in patients' brains after six months, confirming the omega-3 reached its intended target.' (news.keckmedicine.org)
• CNN health reporting corroborates: 'Measures of DHA levels in cerebrospinal fluid...rose by an average of 17% after six months, confirming the omega-3 reached its intended target.' (cnn.com, June 18, 2026)
• MedicalDialogues cites the peer-reviewed source directly: the paper is titled 'CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia,' published in eBioMedicine (DOI: 10.1016/j.ebiom.2026.106316).
• MedicalXpress notes the trial enrolled 365 participants and that '2,000 mg/day DHA increased cerebrospinal fluid DHA by 17%' — consistent with the claim's figures.
• The trial's primary outcome was explicitly the '6-month CSF DHA-to-arachidonic acid (AA) ratio change,' confirming that the 17% CSF measurement was a pre-specified, primary endpoint of the study.

All corroborating sources are reporting on the same single trial; independent replication of the 17% CSF DHA figure in a separate study has not yet occurred, and the full underlying dataset in eBioMedicine was not directly accessible to review raw statistics.

Multiple authoritative sources — including the original institutional press release from Keck Medicine of USC, EurekAlert, CNN Health, and MedicalXpress — consistently confirm the claim. A two-year, randomized, double-blind, placebo-controlled trial (n=365) published in eBioMedicine found that high-dose DHA fish oil supplements did not improve memory or cognitive performance, and brain scans showed hippocampal shrinkage proceeded at the same rate in both the supplement and placebo groups. Notably, DHA was confirmed to have reached the brain via cerebrospinal fluid, ruling out poor bioavailability as an explanation.

• StudyFinds reports that cognitive scores rose nearly identically in both groups (2.76 points on DHA vs. 2.67 on placebo), with no significant difference — a gap described as 'so small as to be meaningless.'
• MedicalXpress summarizes the trial: 'a two-year, placebo-controlled, double-blind study… showed that high doses of omega-3s did not improve memory, cognitive function or brain cell loss in areas of the brain related to Alzheimer's.'
• Brain imaging confirmed that hippocampal shrinkage ran at the same rate in both the DHA and placebo groups over the two-year period (StudyFinds / eBioMedicine).
• Lead investigator Dr. Hussein Yassine (USC Keck School of Medicine) stated: 'Even when we saw high levels of omega-3 in the brains of the treatment group, it did not improve cognition' (CNN Health).
• The study enrolled 365 adults aged 55–80 at elevated Alzheimer's risk who rarely consumed fish, and was published in the peer-reviewed journal eBioMedicine (DOI: 10.1016/j.ebiom.2026.106316).
• No specific cognitive domain — including memory, attention, language, or spatial reasoning — showed a treatment benefit; APOE ε4 carriers and non-carriers responded the same way (StudyFinds).

The full peer-reviewed eBioMedicine paper itself was not directly accessed, so confidence intervals, complete statistical tables, and any pre-specified secondary analyses have not been independently verified beyond what is reported in press releases and science journalism.

Both parts of the claim are well-supported. The 47% APOE4 carrier figure is confirmed directly by multiple independent news sources reporting on the same published study (USC/eBioMedicine, 2026). The characterisation of APOE4 as 'the strongest known genetic risk factor for late-onset Alzheimer's' is corroborated by numerous peer-reviewed papers and a 2025 Nature Medicine article, making it one of the most consistently replicated findings in Alzheimer's genetics research.

• Keck Medicine of USC and MedicalXpress both independently report that 'about half (47%) carried an APOE4 gene, the strongest genetic risk factor for late-onset Alzheimer's' in the study cohort of 365 adults.
• A 2025 Nature Medicine article states: 'The APOE ε4 genetic variant is the strongest genetic risk factor for late-onset Alzheimer's disease.'
• A peer-reviewed PMC review (2025) calls APOE4 'the most robust and widely replicated genetic risk factor for late-onset Alzheimer's disease susceptibility.'
• A 2025 medRxiv preprint states APOE4 is 'the strongest, common genetic risk factor for late-onset Alzheimer's disease,' with one copy increasing risk ~4-fold and two copies ~12-fold in European-ancestry populations.
• The Whitehall II study (PMC, 2021) confirms: 'approximately 25% of the general population carries at least one ε4 allele,' consistent with the study recruiting a higher-risk, enriched sample where 47% carry the allele.
• A peer-reviewed paper in PMC (Journal of Molecular Biology, 2019) states: 'the ε4 variant of the apolipoprotein E gene is the strongest genetic risk factor for the development of late-onset AD.'

The 47% figure is an internal study statistic from the published paper and cannot be verified independently of the study's own data; all secondary sources reporting it trace back to the same USC research team's press materials.